NASDAQ:SCLX Scilex (SCLX) Stock Price, News & Analysis $0.97 +0.01 (+1.04%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Scilex Stock (NASDAQ:SCLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Scilex alerts:Sign Up Key Stats Today's Range$0.95▼$1.0150-Day Range$0.79▼$1.1552-Week Range$0.73▼$2.63Volume2.08 million shsAverage Volume2.28 million shsMarket Capitalization$186.30 millionP/E RatioN/ADividend YieldN/APrice Target$11.33Consensus RatingBuy Company OverviewScilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Scilex Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks57th Percentile Overall ScoreSCLX MarketRank™: Scilex scored higher than 57% of companies evaluated by MarketBeat, and ranked 503rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingScilex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageScilex has only been the subject of 2 research reports in the past 90 days.Read more about Scilex's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Scilex are expected to grow in the coming year, from ($0.75) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scilex is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scilex is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Scilex's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.46% of the float of Scilex has been sold short.Short Interest Ratio / Days to CoverScilex has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Scilex has recently increased by 9.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScilex does not currently pay a dividend.Dividend GrowthScilex does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.46% of the float of Scilex has been sold short.Short Interest Ratio / Days to CoverScilex has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Scilex has recently increased by 9.75%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment0.85 News SentimentScilex has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Scilex this week, compared to 2 articles on an average week.Search Interest5 people have searched for SCLX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows8 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Scilex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,234.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.73% of the stock of Scilex is held by insiders.Percentage Held by Institutions69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Scilex's insider trading history. Receive SCLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter. Email Address SCLX Stock News HeadlinesJaisim Shah Purchases 32,000 Shares of Scilex Holding (NASDAQ:SCLX) StockOctober 30 at 5:21 AM | insidertrades.comScilex Holding (NASDAQ:SCLX) Director Yue Alexander Wu Acquires 20,000 SharesOctober 21, 2024 | insidertrades.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Insider Buying: Scilex Holding (NASDAQ:SCLX) Insider Acquires 30,000 Shares of StockOctober 18, 2024 | insidertrades.comPleasing Signs As A Number Of Insiders Buy Scilex Holding StockOctober 30 at 1:14 PM | finance.yahoo.comScilex announces successful end of Phase II meeting with FDAOctober 30 at 1:14 PM | markets.businessinsider.comScilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with October 30 at 6:00 AM | globenewswire.comScilex Holding (NASDAQ:SCLX) Insider Jaisim Shah Purchases 32,000 Shares of StockOctober 30 at 5:23 AM | americanbankingnews.comSee More Headlines SCLX Stock Analysis - Frequently Asked Questions How have SCLX shares performed this year? Scilex's stock was trading at $2.04 on January 1st, 2024. Since then, SCLX stock has decreased by 52.4% and is now trading at $0.9714. View the best growth stocks for 2024 here. How were Scilex's earnings last quarter? Scilex Holding (NASDAQ:SCLX) announced its earnings results on Tuesday, August, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. The firm had revenue of $16.37 million for the quarter, compared to analysts' expectations of $13.17 million. Who are Scilex's major shareholders? Top institutional shareholders of Scilex include Donald L. Hagan LLC (0.07%). Insiders that own company stock include Henry Ji, Jaisim Shah, Jay Chun, Yue Alexander Wu and Stephen Hoi Ma. View institutional ownership trends. How do I buy shares of Scilex? Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Scilex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scilex investors own include Rigetti Computing (RGTI), Pfizer (PFE), BioNTech (BNTX), Hertz Global (HTZ), Barrick Gold (GOLD), Nikola (NKLA) and BlackBerry (BB). Company Calendar Last Earnings8/13/2024Today11/02/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCLX CUSIPN/A CIK1820190 Webwww.scilexholding.com Phone650-516-4310FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$14.00 Low Stock Price Target$7.00 Potential Upside/Downside+1,066.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,330,000.00 Net Margins-233.88% Pretax Margin-233.86% Return on EquityN/A Return on Assets-111.82% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.19 Sales & Book Value Annual Sales$46.74 million Price / Sales3.99 Cash FlowN/A Price / Cash FlowN/A Book Value($1.10) per share Price / Book-0.88Miscellaneous Outstanding Shares191,790,000Free Float175,048,000Market Cap$186.30 million OptionableOptionable Beta1.14 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:SCLX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.